Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)Axel Grothey, Mark Kozloff, Wei Dong et al.|Journal of Clinical Oncology|2008Cited by 695
Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE)Eric Hedrick, Axel Grothey, Mark Kozloff et al.|Journal of Clinical Oncology|2006Cited by 87
Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE)Axel Grothey, M. Kozloff, Wei Dong et al.|Journal of Clinical Oncology|2007Cited by 55